FTSE 100 Live 06 February: Index higher ahead of interest rates decision, AstraZeneca results AstraZeneca today reported a “very strong performance” for 2024 after total revenues rose 21% to $54.1 billion (£43.3 billion) and earnings lifted 19%.
The company issued guidance for 2025 showing that total revenues are expected to increase by a high single-digit percentage and core earnings per share by a low double-digit percentage, both at constant exchange rates.
The FTSE 100 index is set to make a swift return towards record territory after IG Index futures forecast a rise of 58 points at the opening bell.
Chief executive Pascal Soriot added that the current year will mark the beginning of an “unprecedented, catalyst-rich period” for the company as it sets about targeting revenues of $80 billion by the end of the decade.
In 2025, the company anticipates the first late-stage trial data for seven new medicines along with several important new indication opportunities for existing medicines.
